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Abstract 
It is well-established that high adherence to HAART is a major determinant of virological and 
immunological success. Furthermore, psycho-social research has identified a wide range of 
adherence factors. Our objective was to assess the bi-directional relationship between 
adherence and response to treatment among patients enrolled in the ANRS CO8 APROCO-
COPILOTE study. An econometric approach was implemented through a bivariate two-
equation simultaneous system, studying the factors associated with both adherence and 
undetectability of HIV plasma viral load. Our results highlight that good biological results 
induced by adherence reinforce continued adherence. This strengthens the argument that 
patients who do not experience rapid improvements in their immunological and clinical 
statuses after HAART initiation should be prioritized when developing adherence support 
interventions. Furthermore, it rules out the hypothesis that HAART leads to “false 
reassurance” among HIV infected patients. 
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INTRODUCTION 
Since the introduction of highly active antiretroviral treatment (HAART), adherence to 
medication has become a major treatment issue for HIV-infected patients. Epidemiological 
and clinical research has established that high adherence to HAART is a prerequisite for 
clinical and biological treatment success at the individual level1-3 and has a positive effect on 
public health, as non-adherence may facilitate the development of viral strains resistant to 
current therapies4. Furthermore, psycho-social research has identified a wide range of socio-
economic, cognitive, attitudinal and behavioral factors -including patient beliefs about 
HAART effectiveness- which are significantly associated with adherence in various patient 
groups and cultural contexts5. 
 
Previous research has principally focused on methods which separately identify factors 
associated with either treatment effectiveness1-3 or adherence5. However, such methods do not 
fully explore the true bi-directional relationship between both these phenomena, ignoring the 
fact that effectiveness may well be “endogenous” to adherence, i.e. that adherence behavior 
may itself be influenced by the impact of treatment benefits embodied in biological and/or 
clinical outcomes. Patients may be more motivated to adhere to treatment if they experience 
positive clinical and biological treatment results6 and/or receive positive information about 
treatment effectiveness.  
 
The econometric approach7, using simultaneous multiple equations to control for potential 
endogeneity,  may be more appropriate than current bio-statistical models for evaluating the 
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bi-directional relationship between adherence and HAART effectiveness, as it enables the 
identification of predictors of adherence and controls for the impact of adherence on treatment 
success. 
The French ANRS CO8 APROCO-COPILOTE cohort study8, which followed HIV-1 positive 
patients from HAART initiation, provided the opportunity to compare a “standard” statistical 
model (Generalized Estimated Equation -GEE-) with an econometric simultaneous two-
equation model in a longitudinal study of adherence. 
 
MATERIALS AND METHODS 
The French ANRS CO8 APROCO-COPILOTE 
The cohort was designed to study the clinical, immunological, virological, and socio-
behavioral progression of disease in HIV-1 positive individuals who started a treatment 
regimen (enrollment=M0) including a protease inhibitor (PI)1 in 47 centers throughout France 
between May 1997 and June 1999. Only PI-naive patients were included. Patients with acute 
HIV syndrome were excluded. Medical and socio-behavioral data were gathered at months 0 
(i.e. M0), 1, 4, 12, 20, 28, 36, 44, 48, 52, 60, 72, 84, 96, 108, corresponding to patient visits. 
We analyzed data collected until December 2006. 
 
Medical data. At each patient visit, the HIV care provider listed the antiretroviral regimen 
prescribed and completed a medical questionnaire which included clinical and laboratory data 
(CDC clinical stage, CD4 cell count, Viral Load -VL-). All VL levels were prospectively 
                                                          
1
 In 1997, the only triple therapy available was a PI based regimen. Therefore, this cohort corresponds to the first 
generation treated with HAART in France. 
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measured by the assay routinely available in each center. Three assays were approved in 
France at study initiation: RT-PCR (Amplicor, Roche), bDNA (Quantiplex, Chiron) and 
Nasba, with lower limits of detection of 200, 500 and 400 copies of HIV-1 RNA/ml 
respectively. VL titers were considered undetectable if they were lower than the threshold 
values specific to each center’s assay. The medical questionnaire at enrollment collected 
retrospective data about each patient’s HIV history: transmission category, time since 
diagnosis and antecedents of antiretroviral treatment. 
 
Socio-behavioral data. At enrollment, a self-administered patient questionnaire collected 
social and demographic information including age, gender, education, marital status, 
employment status and housing conditions. It also collected information about depressive 
symptoms, alcohol consumption, HIV-related self-reported symptoms, and beliefs9 regarding 
treatment effectiveness. This information was updated using identical questions at each 
follow-up visit. 
Depression was measured using the French version of the Center for Epidemiologic Studies 
Depression Scale (CES-D), a 20-item scale10 commonly used in studies involving HIV-
infected patients. Although not a tool for clinically diagnosing depression, a CES-D score ≥16 
is considered indicative of significant depressive symptoms. 
Two questions examined alcohol consumption over the previous 7 days (frequency and 
quantity). Patients were considered daily drinkers if their average daily alcohol consumption 
was ≥1 units 11. 
 
 8
A French version of the 13-item HIV symptom index12-15 collected information about self-
reported symptoms. From month 1 (M1) onwards, patients reported any experience they had 
had in the previous 4 weeks of the following symptoms: diarrhea, nausea, stomach pain, 
headache, taste change, itching skin, muscle pain, heartburn, mouthsores, vomiting, fever, 
kidney stones or fatigue. The sum of all these self-reported symptoms was scored to 
quantitatively assess perceived side effects. The patient questionnaire also contained a 
separate list of nine symptoms related to possible manifestations of lipodystrophy16. 
From M1 onwards, patients rated HAART treatment as very effective, effective, somewhat 
effective and ineffective. As few patients (<5% at each interview) reported the latter two 
options, the variable was dichotomized (very effective versus other). 
Five questions about treatment adherence were also included in all self-administered 
questionnaires, in accordance with the AIDS Clinical Trial Group17 methodology. Patients 
were first asked to fill out a detailed table, writing down the number of pills they had actually 
taken during the previous four days, for each drug in their HAART regimen. Then, on a 4-
point scale they indicated whether they had “totally”, “almost totally”, “partially” or “not at 
all” taken their prescribed doses of HAART. They were also asked if they had ever taken their 
full daily dose of prescribed drugs all at once during the same period and whether they had 
not followed their medication schedule on several occasions. Finally, they were asked 
whether they had skipped a dose during the previous weekend. As self-questionnaires tend to 
underestimate non-adherence due to memory bias, we used a dichotomous measure of 
adherence in order to have a robust measure of adherence for statistical analysis18. Patients 
were classified as “adherent” if they detailed that they had taken 100% of their prescribed 
doses. Among these patients, those who subsequently declared that they: a) had skipped a 
dose during the previous week-end b) had “almost totally” followed their HAART regimen, c) 
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did not follow their medication schedule on several occasions or d) took their full daily dose 
all at once on at least one occasion during the four days prior to the visit, were all reclassified 
as “non-adherent”. All other patients were classified as “non-adherent”. 
 
Statistical analysis 
GEE models 
Two separate equations using adherence and treatment effectiveness respectively as the 
dependent variables and employing the dichotomized variables (“adherent” versus “non- 
adherent” and “undetectable” versus “detectable” VL respectively) were first estimated using 
GEE models19,20. GEE has been widely used in the biostatistical literature21 as it takes into 
account intra-individual correlations between repeated observations in longitudinal settings. It 
is a semi-parametric approach using an extension of the quasi-maximum likelihood22-24 
method to longitudinal data. In our estimations, we used a probit link. In order to select a 
working correlation structure R, we first calculated the Quasi-likelihood Information Criterion 
(QIC)25 for several popular working correlation structures including an independent (R = I), 
an exchangeable ( ,jkR j kα= ≠ ), and a first-order autoregressive    ( ,j kjkR j kα −= ≠ ) 
working correlation matrix. We chose to use the correlation structure with the smallest QIC 
for our analysis. 
 
Econometric model 
To capture the extent of bi-directional interaction between adherence and treatment 
effectiveness, we applied a simultaneous two-equation model to the same set of data. In this 
joint model, the longitudinal nature of data was taken into account through a random-effects 
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specification26-28. Hence, we estimated the following random-effects bivariate probit model:
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where 1=itADH if the individual i is highly adherent at time t ( 0=itADH  if the individual i is 
not) and 1=itEFF  if treatment effectiveness is high at t (i.e. if viral load is undetectable at t) (
0=itEFF  if viral load is detectable at t). We assume that *itADH is determined by a set of 
exogenous variables itx1 , and 
*
it
EFF
 is simultaneously determined by *itADH and a set of 
exogenous variables itx2 . If adherence and treatment effectiveness interact bi-directionally, 
then correlated error terms are expected, i.e. some unobserved variables correlated with one 
another may explain both the patient’s adherence behavior and his/her treatment response. For 
instance, patients who naturally tend to invest in healthcare may have a greater tendency to be 
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highly adherent and may show a better response to treatment. The random-effects 
specification implies that error terms are decomposed both in unobserved individual specific 
effects iv  and time-specific chance events itη . Hence the correlation between residuals might 
be induced by either the correlation between patient-specific disturbances (e.g. a “structural 
propensity” for investment in one’s own health) or between time-specific residuals (e.g. a 
change in treatment experience and/or illness between two time periods). Note that x1it 
represents a set of instruments for ADHit. In contrast to the two-equation model, a separate 
estimation of both the adherence and effectiveness equations would lead to asymptotically 
biased estimates if their disturbances were correlated. 
It should be acknowledged that the recursive system (I) used in this simultaneous two-
equation model (one dependent variable of one equation present on the right-hand side of the 
other equation) is logically consistent, in turn implying that a reduced form exists. 
Furthermore, it can be fully identified7, i.e. there is a unique way to recover the structural 
form parameters from the reduced equation. As our model involved dichotomous dependent 
variables, for which standard instrumental techniques are inappropriate7, we used a full 
information method of estimation. This  estimation, performed using the “bivariate” 
command in LIMDEP version 9.0. , treats all equations and parameters jointly, thus ensuring 
that the most efficient estimates are obtained. 
 
Empirical estimations 
Estimations were performed over a 9-year period (M1 – M108).  
In both the GEE and econometric models, patient, disease and treatment-related factors -all 
found to be significantly related to adherence in previous research- were initially introduced 
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into the adherence equation21. Patient variables included: age, educational level, employment 
status, housing conditions, marital status, being a migrant, depression status and finally, level 
of alcohol consumption. Disease-related variables included: HIV transmission mode, time 
since HIV diagnosis at inclusion and CDC clinical stage. Treatment-related factors included: 
whether the patient was HAART naive or not at inclusion, and, for each visit - a) the number 
of perceived toxicity-related symptoms and b) whether she/he was still receiving a regimen 
including a PI. In addition, patients’ “subjective” beliefs regarding treatment effectiveness 
and “objective” measures of treatment success (i.e. increased CD4 cell counts since inclusion) 
were used. This latter measure referred to the most recent test results known to the patient 
before making a decision concerning drug intake at t and thus were indexed at t-1. As HIV-
infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination 
antiretroviral therapy have mortality rates similar to those of the general population29, we also 
tested the variable CD4t-1> 500-yes/no as an alternative to continuous CD4 cell count gains. 
Furthermore, we tested the interaction between “objective” and “subjective” treatment 
effectiveness measures. 
 
In both models, the following variables, known to affect HAART effectiveness (i.e. whether 
VL was undetectable or not), were initially introduced in the treatment effectiveness equation: 
patient’s age; VL and CD4 cell count at baseline; clinical stage at each assessment; being 
HAART naive at inclusion; whether the patient received a treatment including Invirase2 at 
inclusion; time since initial HIV diagnosis at baseline; duration of exposure to HAART; 
variables related to co-morbidities and/or psychological health status (co-infection with 
Hepatitis C Virus, depression) during the course of treatment. Naturally, the adherence 
variable itself was also introduced into the treatment effectiveness equation. 
                                                          
2Unboosted saquinavir (Invirase) has been shown  to be less effective than other PIs30 
 13 
 
RESULTS 
Descriptive Analysis 
The study comprised 1,026 patients. Table 1 describes their baseline socio-demographic and 
clinical characteristics. 
The proportion of patients treated with PIs declined over the full study period (M12=88%, 
M108=48%), despite all initiating HAART with regimens including at least one PI. At M1, 
35% received a twice-daily regimen, the other 65% having a minimum of 3 daily doses. At 
M108, 32% were prescribed a once daily regimen, 67% twice-daily and only 1% more than 3 
daily doses. 
At M108, 73% had an undetectable plasma VL (Figure 1). Although the aggregated 
percentages of patients with this virological outcome stabilized at >60% after M12, analysis 
of individual patient paths revealed certain state changes (i.e. VL increases after periods 
where it had been controlled). Descriptive statistics (Figure 1) also suggest an evolution in the 
percentage of highly adherent patients over the study period: 65% at M0, 54% at M4 and then 
a progressive increase to peak at 67% by M28. Thereafter it stabilized at around 65% except 
during the last two observation periods (M96, M108) where percentages of highly adherent 
individuals had significantly increased (73%), due perhaps to the possibility that those still 
participating at M96 and M108 were better adherers than those who had dropped out. This 
point is explored in more detail in the discussion section. 
 
Figure 2 shows that CD4 cell count after baseline increased quickly over the whole study 
population until M36, the median increase being 235 cells/mm3. It then stabilized at around 
270 cells/mm3. Figure 2 also shows a significant positive relationship at most visits between 
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increased CD4 cell count after baseline and subjective patient beliefs about HAART 
effectiveness. Those deeming treatment to be very effective had, logically,  higher CD4 gains. 
 
Over the whole study period (M1 – M108), the median number of self-reported side-effects 
varied between 3.8 and 9.8. No side-effects were reported in only 6% of all assessments. A 
third of the respondents reported depressive symptoms at every visit.  
 
 
Comparison of separate and joint multivariate estimations 
Estimations were based on a total of 4,770 observations. Each patient attended an average of 
5.6 visits during the study period. Table 2 presents both the separate estimations of adherence 
and virological success of HAART using GEE as well as the joint estimation of these same 
two variables, based on the simultaneous equation econometric model. Column (i) presents 
the specification where CD4 cell count gain was introduced separately. Column (ii) presents 
the specification containing the interaction between CD4 cell count gain and subjective 
beliefs about treatment effectiveness. 
 
A number of variables previously found to be “determinants” of adherence were identified 
using the GEE model: older age31, living in a stable relationship32, HAART regimens with 
fewer daily drug intakes21 and positive beliefs about the effectiveness of HAART14 were all 
significantly associated with high adherence. Instead, depressive symptoms33 and daily 
alcohol consumption5 were associated with poor adherence. Table 2 shows that these same 
variables were also found to be significantly related to adherence in the joint econometric 
estimation. This latter model also highlighted certain additional social (e.g. poor housing 
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conditions), clinical (e.g. shorter time since initial HIV diagnosis, treatment with PI-
containing HAART regimen, less advanced HIV clinical stage, HIV-infection through 
injecting drug use33) and adverse event (e.g. higher number of self-perceived side-effects13) 
variables significantly associated with poor adherence. Although immunological parameters 
did not reach the level of statistical significance (either directly or when crossed with patient 
beliefs about HAART effectiveness), in the GEE estimation of adherence, CD4 cell count 
gain after baseline as well as interaction between immunological status and patient beliefs 
about HAART effectiveness were both found to influence adherence in the joint estimation. 
After adjustment for all other factors, even those patients who had subjective doubts about 
HAART effectiveness tended to be more adherent when they were aware of their CD4 cell 
count gains. Similar results were obtained when substituting the continuous variable (CD4 
cell count gain after baseline) with a CD4 cell count level higher than 500 (whether reached 
by patients or not).  
Table 3 displays the Quasi-likelihood Information Criterion (QIC) for three different working 
correlation structures using both the adherence and effectiveness equations. Analysis of the 
table suggests that the “exchangeable” structure should be favored. In turn this result supports 
the use of the random-effects specification, which also assumes that the correlations between 
any two observations are stable. When patient heterogeneity is modeled explicitly through the 
random-effects specification, our results underline that unobserved patient characteristics 
significantly account for adherence behavior. It should also be stressed that in the 
simultaneous model, the co-variances between disturbances of both equations (Table 2) are 
significant, thus confirming the statistical appropriacy of taking the endogenous nature of 
adherence into account3. On the one hand, the correlation between patient-specific error terms 
                                                          
3Endogeneity is supported by a Hausman test, run on the corresponding linear probability model to examine 
whether adherence is an exogenous variable in the effectiveness equation. This test led to the exogeneity of 
adherence being rejected (significance level p = 0.0004).  Specification (ii) (see Table 2) was used for the test. 
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is positive and significant,  suggesting that intrinsic patient features result in some patients 
being both better adherents and respondents to treatment. On the other hand, the correlation 
between time-varying disturbances is positive and significant (Table 2), suggesting that 
unobserved time-varying factors inducing a positive change in health between any two time 
periods are correlated with unobserved factors having a positive impact on adherence 
behavior. This latter effect may indeed capture the indirect impact of improvements in health 
outcomes (EFFit in (I)) on adherence behavior.  
 
Both the separate GEE estimation and the effectiveness equation of the joint model confirm 
the positive impact of adherence on the probability of having an undetectable VL at any visit, 
after adjusting for other biological and clinical factors already known to be predictors of 
HAART success (i.e. lower viral load34, no previous antiretroviral HIV drugs35 and not 
receiving a regimen which included unboosted Invirase at HAART initiation36). Both also 
confirm that depressive symptoms are an independent predictor of a reduced likelihood of 
virological success with HAART. Advanced clinical HIV stage was not associated with 
treatment success in either estimation. Older age, found to be significantly associated with 
HAART effectiveness in the GEE model, was not significant in the joint model whereas 
Hepatitis C Virus co-infection and longer time between HIV diagnosis and HAART initiation 
were both associated with HAART effectiveness in the joint model only.  
 
DISCUSSION 
The diffusion of HAART to treat HIV infection in developed and developing countries has 
generated a huge body of research highlighting not only the importance of high adherence to 
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medical regimens for increased treatment effectiveness but also the complex array of socio-
demographic, psycho-social and cultural factors affecting adherence behaviors. With a few 
exceptions in the study of Viral Load dynamics37-39, the statistical methods commonly used in 
epidemiological and psychosocial research on adherence only permit separate estimations of 
the dependent variables, used as proxies of treatment effectiveness and of adherence, to be 
carried out. 
Simultaneous-equation estimations have already been used in various fields of clinical 
research (e.g. studying the impact of smoking on birthweight40). However, to our knowledge, 
apart from one study showing that the probability of remaining in HIV clinical trials was 
associated with increased CD4 cell count6, no previous research using such econometric 
methods has taken the hypothesis that positive biological and clinical HAART outcomes, as a 
result of high adherence, may themselves reinforce high adherence. 
 
In this study, we compared the application of two estimation methods to the same set of 
longitudinal data from the APROCO-COPILOT cohort study of HIV-infected patients 
initiating a PI-containing HAART regimen. The comparison suggests that a joint estimation 
of adherence and treatment effectiveness, using a two-equation simultaneous econometric 
model controlling for endogeneity, may capture more determinants of adherence than do 
separate GEE estimations, which is the most common method found in the literature. There 
are two main modeling differences between separate GEE equations and joint random-effects 
models. First, the longitudinal nature of the data is modeled differently. The GEE approach 
treats correlations between repeated observations as measurement errors. In the random-
effects approach, individual-specific disturbances are considered the sources of correlations 
between repeated observations. Second, unlike the separate GEE equations, the joint 
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estimation model takes into account a possible reciprocal relationship between adherence and 
treatment effectiveness. One could argue that for a comparison of separate and joint 
estimations it would have been more appropriate to use a random-effects probit model for 
both estimations. Indeed, we did investigate this method and it provided very similar results to 
those of the GEE model presented here. This is not surprising since the conditional mean 
functions are the same for both the GEE and random-effects models41. 
Certain studies in existing psycho-social literature describe contradictory findings about 
adherence determinants. For example some highlight the significant, negative impact of 
depression and alcohol consumption on adherence, whereas others, controlling for these same 
variables, do not14. This may be due to the limitations of statistically separate estimations of 
adherence which do not take into account the reciprocal effect of treatment outcomes on 
adherence behavior itself.  
Furthermore, controlling for endogeneity provided more precise identification of factors 
associated with treatment success and adherence, as the genuine effect of variables can be 
separated from the role of unobserved factors, which explain both treatment success and high 
adherence behavior. This might explain why patient age was significant in our GEE model 
but not so in the joint one - if unobserved factors were partially captured by observed 
variables (such as age) in the separate estimation of the effectiveness equation, then the 
significance of observed variables might well be different in the joint model.  
More importantly, only joint estimation identified a significant relationship between a positive 
HAART immunological outcome and high adherence, suggesting that treatment outcomes 
have a definite impact on adherence behaviors. Previous psycho-social research has already 
emphasized the role of perceived effectiveness of HAART (i.e. patients’ beliefs about the 
benefits and risks of treatment42 and their subjective experience with therapy during 
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treatment12) whose impact on adherence behavior is also confirmed in this study through the 
“time-varying beliefs” variable. However, only joint estimation was able to fully capture the 
longitudinal dynamic of interaction between objective improvements in immunological 
treatment outcomes and subjective perceptions about HAART effectiveness.  
Another added value of applying a joint model to our data is that it not only highlights the 
direct impact of treatment outcomes on adherence through observed variables but also 
underlines the indirect impact of viral outcomes on adherence behavior through the 
correlation between time varying residuals 1itη  and 2itη . This correlation was shown to be 
positive and significant (Table 2). 
From a methodological point of view our results show that a two-equation approach (i.e. the 
joint estimation of adherence and effectiveness equations) may be the most appropriate 
means of capturing the relationship between adherence and treatment outcomes. The random-
effects specification makes performing the joint estimation in a longitudinal framework 
possible. The joint study of two dependent variables requires a structural model: decomposing 
the error term into two parts makes it possible to specify the source of the relationship 
between the two phenomena. In this paper, correlation is assumed to arise from individual-
specific error terms and from temporal disturbances. Note that our econometric modeling 
relies on the normality assumption of residuals. By contrast, the GEE method is not suited to 
handling simultaneity problems. 
It should be acknowledged that the number of adherence observations in our analysis 
decreased over the study, with analysis at M4 and M108 based on 647 and 104 observations, 
respectively (Figure 1).  
This decrease can be accounted for by three main phenomena: missed clinical visits, 
incomplete self-administered questionnaires and study drop-out (death or lost to follow-up). 
Consequently, checking for selection bias in our results is important: if poor adherers are 
responsible for missing data, our estimations may be biased. To control for this, we estimated 
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a trivariate probit model which included a selection equation (i.e. a missingness equation). 
Baseline fixed variables, last available CD4 cell count and viral load were all considered in 
order to identify the variables associated with missing data, for whatever reason, at any visit. 
We tested whether the correlation between the adherence and selection equations and the 
correlation between the effectiveness and selection equations were jointly equal to zero. With 
the test’s p-value equaling 0.07, we concluded that our results were not affected by a selection 
bias. Note that the trivariate probit model was not estimated on panel data. 
Our model of adherence behavior assumes that past experience of adherence has no effect on 
current adherence behavior. In order to evaluate this assumption, we tested whether ADHit-1 
had an impact on ADHit. We applied Wooldridge’s 43 approach which led us to estimate the 
following model: 
itiiiititit axADHADHxADH 113
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where ADHi1 is the observation of adherence at date 1 (i.e. the initial observation) and '1ix  the 
average of the explanatory variables over time. 
We found that ADHi1  and ADHit-1 did not have a significant effect on ADHit , as suggested 
both by the individual p-values and the Wald test evaluating whether the coefficients of 
ADHi1 and ADHit-1 were jointly equal to zero. Therefore we may conclude that being adherent 
in the past is not a key factor to current adherence behavior. Note however that we also found 
that time invariant patient inertia affected adherence behavior (i.e. some individuals had a 
greater tendency to be adherent at all assessments).  Further research into the roles of state 
dependency and unobserved heterogeneities for adherence behaviors is required.  
 
Beyond these methodological aspects, the demonstration of a bi-directional relationship 
between HAART adherence and effectiveness has two major implications for both clinical 
practice and psycho-social interventions aimed at reinforcing adherence behaviors. First, it 
strengthens the argument that patients not experiencing rapid improvements in their 
immunological and clinical statuses after HAART initiation should be prioritized when 
implementing adherence support interventions. Such interventions should start as soon as 
possible after treatment initiation and may be more cost-effective in that subgroup of patients, 
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as they would induce a “virtuous” circle between treatment adherence and effectiveness. This 
may also be particularly useful in low-resource settings faced with HAART delivery logistical 
issues. Second, this bi-directional relationship invalidates the hypothesis that HAART may 
lead to “false reassurance” among HIV-infected patients, i.e. that patients may become less 
adherent when they start experiencing good treatment outcomes. In reality, the opposite is 
true. This fact supports the argument for focusing interventions targeting the prevention of 
treatment failure, due to a lack of adherence, on those patients who do not experience the best 
improvements in their health status. Of course, our results come from analysis of data from a 
cohort of HIV individuals living in a developed country which provides a relatively high level 
of information and early access to HAART. Further research is required to verify whether our 
results hold for other HIV-positive populations. Our approach may also be useful for all 
chronic diseases where treatment effectiveness is dependent on long-term adherence to care 
and medication and where treatment benefits (including improved health status and quality of 
life) may in turn positively influence such adherence.  
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Table 1: Population description at baseline (n = 1, 026) and Treatment characteristics at 
Month 1  
 
Baseline characteristics Mean (SD) Median %
Age (years) 37.5 (9.5) 36.0
Male 77.5%
Born in an European Union  country 72.0%
University degree 17.0%
Married or living with a partner 52.9%
Employed 54.0%
Depressed (CES-D score ≥ 16) 42.0%
Daily alcohol consumption 18.0%
Time since HIV seropositivity was detected (months) 56.6 (50.2) 47.0
Co-infected with HCV** 23.1%
HIV transmission: drug injection 17.0%
HIV transmission: homosexual contact 41.0%
HIV transmission: heterosexual contact 32.0%
HIV transmission: other 10.0%
HAART*-naive at inclusion 44.0%
Clinical stage CDC: C 20.0%
CD4 cell count 298.0 (204.0) 279.0
Log10 viral load 4.4 (1.0) 4.5
Treatment characteristics at Month 1
Number of drug intake each day  >2 64.7%
Number of self-perceived side effects 4.5
*Highly Active Antiretroviral Therapy
**Hepatitis C virus
Table 2: Estimations of the adherence and treatment equations (separate models and joint estimations) 
(n = 4770) 
 
 
coef p coef p coef p coef p
ADHERENCE EQUATION (dependent variable adherent = 1)
Age at t 0.03 <0.01 0.03 <0.01 0.03 <0.01 0.03 <0.01
Has a university diploma a t -0.04 0.57 0.00 0.99 -0.04 0.60 0.00 0.99
Is employed at t -0.01 0.77 0.04 0.32 0.02 0.75 0.04 0.33
Has good housing conditions at t 0.03 0.12 0.04 0.04 0.04 0.10 0.04 0.04
Married or living with a partner at t 0.13 <0.01 0.21 0.00 0.15 <0.01 0.21 <0.01
Born in a European Union country 0.04 0.91 0.06 0.28 0.04 0.95 0.06 0.28
HIV transmission: drug injection -0.21 0.08 -0.12 0.05 -0.21 0.07 -0.12 0.05
HAARTc-naive at inclusion -0.02 0.78 -0.06 0.19 -0.02 0.78 -0.06 0.19
Time since HIV seropositivity was detected at baseline 0.00 0.48 0.00 0.03 0.00 0.49 0.00 0.03
Depressed at t (CES-D score ≥ 16) -0.21 <0.01 -0.26 <0.01 -0.21 <0.01 -0.26 <0.01
Daily alcohol consumption at t -0.13 0.05 -0.14 0.02 -0.12 0.05 -0.14 0.02
IPd in HAARTc treatment at t -0.08 0.08 -0.09 0.05 -0.08 0.09 -0.09 0.05
Number of drug intake each day  at t: >2 -0.24 <0.01 -0.28 <0.01 -0.23 <0.01 -0.28 <0.01
Number of self-perceived side effects at t -0.01 0.18 -0.01 0.01 -0.01 0.20 -0.01 0.01
Clinical stage CDC at t : C 0.15 0.06 0.18 <0.01 0.15 0.05 0.18 <0.01
CD4 > 200 at baseline 0.05 0.58 0.06 0.28 0.04 0.57 0.06 0.28
(CD4t-1 - CD4t0)/1000 0.17 0.06 0.44 <0.01
(CD4t-1 - CD4t0)/1000 when HAARTc is believed to be very effective 0.21 0.11 0.43 <0.01
(CD4t-1 - CD4t0)/1000 when HAARTc is believed to be 
effective/somewhat effective/ineffective 0.26 0.06 0.45 <0.01
Believes that  HAARTc treatment is very effective at t 0.10 0.09 0.15 <0.01 0.10 0.09 0.16 0.01
t 0.00 0.47 0.00 0.28 0.00 0.47 0.00 0.28
     
0.83b 0.83b
EFFICACY EQUATION (dependent variable: undetectable VL = 1, detectable VL = 0)e
Is adherent (versus non adherent) between( t-1 ) and t 0.13 <0.01 1.11 <0.01 0.14 <0.01 1.11 <0.01
Age at t 0.01 <0.01 0.00 0.71 0.01 0.01 0.00 0.71
Log10 viral load at baseline -0.13 <0.01 -0.16 <0.01 -0.13 <0.01 -0.16 <0.01
CD4 > 200 at baseline 0.08 0.23 0.03 0.55 0.08 0.29 0.03 0.55
Clinical stage CDC at t : C 0.09 0.24 0.08 0.17 0.09 0.25 0.08 0.17
HAARTc naive at inclusion 0.57 <0.01 0.72 <0.01 0.57 <0.01 0.72 <0.01
Has a treatment including Invirase at baseline -0.23 <0.01 -0.26 <0.01 -0.22 0.02 -0.26 <0.01
Co-infected with HCVf  at t 0.11 0.36 0.21 <0.01 0.11 0.21 0.21 <0.01
Depressed at t - 1 (CES-D score ≥ 16) -0.15 <0.01 -0.15 <0.01 -0.14 <0.01 -0.15 <0.01
Time since HIV seropositivity was detected at baseline 0.00 0.21 0.00 0.04 0.00 0.21 0.00 0.04
t 0.00 <0.01 0.00 <0.01 0.00 <0.01 0.00 <0.01
0.92b 0.92b
Covariance between individual effects 0.07 <0.01 0.07 <0.01
Covariance between error terms 0.10 <0.01 0.10 <0.01
aGeneralized Estimated Equation (exchangeable correlation matrix)
bsignificant (likelihood ratio test)
cHighly Active Antiretroviral Therapy
dProtease Inhibitor
e<200, 400 or 500 copies of HIV-1 RNA /ml depending on the center
fHepatitis C virus
In specification (i)  the variable (CD4t - CD4t0) is included as a plain covariate (i.e. not interacted with another covariate) in the adherence equation
In specification (ii)  the interaction terms between the variable (CD4t - CD4t0) and patient beliefs about treatment efficacy are introduced
We also excluded from the models those covariates  which proved to be not statistically significant.
The results on the remaining significant variables were not qualitatively different for either the separate or joint estimations
Separate 
estimations 
using GEEa
Joint model 
(random-effects 
bivariate probit model)
(i) (ii)
Separate 
estimations 
using GEEa
Joint model 
(random-effects 
bivariate probit model)
1vσ
2vσ
  
Table 3: Quasi-likelihood Information Criterion (QIC) for various candidate working 
correlation structures 
 
 
  
  
Independent Exchangeable First-order autoregressive
Adherence equation QIC 6894 6888 6890
Efficacy equation QIC 7657 7631 7674
Working correlation matrix
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Figure 1: Evolution of the percentage of highly adherent patients and of the percentage of 
patients with undetectable viral load from Month 1 (M1) to Month 108 (M108) 
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Figure 2: Median increase in CD4 cell count since Month 0 (M0) and p values of the 
Wilcoxon  rank sum test comparing patients rating HAART as very effective and those rating 
HAART as effective/somewhat effective and ineffective 
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